This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 May;11(5):407-8.

doi: 10.1016/S1470-2045(10)70092-9.

Bravo for PRAVO

Kevin J Harrington, Christopher M Nutting

PMID: 20434708
DOI: 10.1016/S1470-2045(10)70092-9

Comment

Bravo for PRAVO

Kevin J Harrington et al. Lancet Oncol. 2010 May.

. 2010 May;11(5):407-8.

doi: 10.1016/S1470-2045(10)70092-9.

Authors

Kevin J Harrington, Christopher M Nutting

PMID: 20434708
DOI: 10.1016/S1470-2045(10)70092-9

No abstract available

PubMed Disclaimer

Comment on

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K. Ree AH, et al. Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6. Lancet Oncol. 2010. PMID: 20378407 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science